Congratulations to Asia-Lily Boyd for her recent publication in the International Journal of Molecular Sciences.
Triple-negative breast cancer is an aggressive disease with limited treatment options and poor prognosis. Although immune checkpoint inhibitors targeting the PD-1/PD-L1 axis have shown clinical promise, many TNBC patients exhibit resistance or limited response, underscoring the need to understand regulatory mechanisms of PD-L1 expression.
Department of Pathology & Molecular Medicine PhD candidate Asia-Lily Boyd and her colleagues Prem Khanal, Tynan Kelly, Anni Ge and Yawei Hao in Dr. Xiaolong Yang’s group now report in the International Journal of Molecular Sciences that focal adhesion kinase promotes the ability of PD-L1 to reduce T-cell-mediated cancer cell killing. These findings suggest that currently available and clinically approved inhibitors of the focal adhesion kinase could enhance the therapeutic benefits of PD-L1 blockade in the treatment of triple-negative breast cancer patients.
Congratulations to Asia-Lily on this exciting first author publication! Read her published work here: Kinome-Wide Screening Identifies FAK as a Novel Post-Translational Regulator of PD-L1 Stability and Immune Evasion in Triple-Negative Breast Cancer